Evidence map›Paper›PMID 25435112›Full record

ReviewPediatric clinics of North America2015

Treatment of pediatric acute lymphoblastic leukemia.

Stacy L Cooper, Patrick A Brown

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02912676 (A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood, Adolescent, and Adult Lymphoblastic Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia), which is not on this map. Cited by 143 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02912676 phase1 / phase2completednot on this mapstarted 2016, after this paper: background citation

A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood, Adolescent, and Adult Lymphoblastic Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia

TypeinterventionalSponsorKjeld SchmiegelowRan2016 to 2020Enrolled30ConditionsAcute Lymphoblastic Leukemia, Lymphoblastic LymphomaArmsThioguanine (oral)
3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Baseline [European journal of nuclear medicine and molecular imaging · 2026
    Article
  19. Article
  20. Article

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stacy L CooperPediatric Hematology/Oncology, Johns Hopkins/National Institutes of Health, Bloomberg 11379, 1800 Orleans Street, Baltimore, MD 21287, USA.
Patrick A BrownPediatric Leukemia Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 2M49, Baltimore, MD 21231, USA. Electronic address: pbrown2@jhmi.edu.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
LAB RESEARCH TRAINING IN PEDIATRIC ONCOLOGY-HEMATOLOGYT32CA060441 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN D FRIEDMAN · 1993 to 2026
$14.9M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric oncologic diagnosis, and advances in its treatment have led to progressive improvements in survival. The 4 main components of therapy are remission induction, consolidation, maintenance, and central nervous system-directed therapy, and usually last 2 to 3 years. Treatment intensity based on risk-based stratification is the cornerstone of treatment. Patients with features of more favorable disease are spared the more toxic effects of chemotherapy, whereas more aggressive regimens are reserved for those with higher-risk disease. Prognosis of relapsed pediatric ALL depends primarily on duration of remission and site of relapse.

Indexed as

Antineoplastic AgentsChildHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRisk AssessmentTreatment OutcomeAntineoplastic AgentsAcute lymphoblastic leukemiaLeukemia treatmentRisk-based stratification

Identifiers

PMID25435112
PMCPMC4366417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.